Ezetimibe/obicetrapib (NewAmsterdam Pharma)

N/A

Report date: 2026/04/08 15:42:03

Base Information

Drug NameEzetimibe/obicetrapib (NewAmsterdam Pharma)
Drug Alias Nameobicetrapib/ezetimibe (NewAmsterdam Pharma)FDC (NewAmsterdam Pharma)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNiemann-Pick C1-like protein 1 inhibitorsCholesterol absorption inhibitorsCholesteryl ester transfer protein inhibitors
TargetsNiemann-Pick C1-like protein 1Cholesteryl ester transfer protein
Therapy Area/IndicationsPlaque, AtheroscleroticHypercholesterolemiaDyslipidemias +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEU
CombinationsYes EzetimibeObicetrapib
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesNewAmsterdam Pharma BV
China Registration ClassN/A

Develop Information

Active CompaniesNewAmsterdam Pharma Co NVNewAmsterdam Pharma BV
Inactive CompaniesN/A
Active IndicationsPlaque, AtheroscleroticHypercholesterolemiaDyslipidemias +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A